In the subgroup analysis by cancer type, a worse 3-year overall survival of Gli1 positivity was observed in breast cancer (n = 6, OR: 1.63, 95% CI: [1.09, 2.45], P = 0.02, I2 = 1%), cancer of digestive tract (n = 8, OR: 3.51, 95% CI: [1.97, 6.24], P < 0.0001, I2 = 44%), liver cancer (n = 5, OR: 3.54, 95% CI: [2.23, 5.63], P < 0.00001, I2 = 0%), pancreatic cancer (n = 3, OR: 2.47, 95% CI: [1.24, 4.92], P = 0.01, I2 = 7%) and ovarian cancer (n = 3, OR: 3.80, 95% CI: [1.50, 9.61], P = 0.005, I2 = 0%) respectively. This evidence concerns the gene GLI1 and cancer.